An update from Adagene ( (ADAG) ) is now available.
Adagene Inc. reported its full-year 2024 financial results and provided a corporate update, highlighting significant progress in its clinical programs. The company announced promising data from its Phase 2 trial of ADG126 in microsatellite stable colorectal cancer (MSS CRC), showing a 33% overall response rate. Adagene’s SAFEbody technology has been instrumental in developing masked T cell engagers with a superior safety profile, and the company is pursuing strategic partnerships to advance these programs. Financially, Adagene reported a cash balance of $85.2 million, providing a runway into late 2026, despite a net loss of $33.4 million for 2024. The company plans to expand its clinical trials and establish additional collaborations in 2025.
More about Adagene
Adagene Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel antibody-based therapies. The company utilizes its proprietary SAFEbody technology to enhance the safety and efficacy of its therapeutic candidates, targeting various cancer indications.
YTD Price Performance: -18.20%
Average Trading Volume: 69,874
Technical Sentiment Signal: Buy
Current Market Cap: $74.6M
See more data about ADAG stock on TipRanks’ Stock Analysis page.